Xin Lang Cai Jing·2026-03-27 06:53Core Viewpoint - Tiger Med has seen a significant increase in its stock price, rising 5% to 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, and a cumulative increase of 6.82% over the past three days [1][5]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][5]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][5]. - The revenue composition of the main business is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][5]. Fund Holdings - Two funds under Nuoan Fund have significant holdings in Tiger Med, totaling 1,001,500 shares. Based on the previous closing price of 50.78 CNY, the current stock price of 53.32 CNY results in a daily floating profit of approximately 2.54 million CNY, with a total floating profit of 3.24 million CNY over the past three days [2][8]. - The Nuoan Selected Return Mixed A fund holds 734,922 shares, representing 0.0995% of the circulating shares and 5.63% of the fund's net value, with no change in the number of shares held [3][7]. - The Nuoan Progressive Return Mixed fund holds 266,600 shares, representing 0.0361% of the circulating shares and 5.14% of the fund's net value, also with no change in the number of shares held [3][7].